Shots:
- The companies plan to initiate a P-II study assessing selgantolimod + VIR-2218 in treatment-experienced and treatment-naïve people living with HBV. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy
- The 1EPs of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of HBsAg and HBV DNA from the serum. The study is the first P-II study that combines immunomodulation and Ag suppression approaches in HBV cure research
- Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the P-II study
Click here to read full press release/ article | Ref: Gilead | Image: Revenues & Profits
The post Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus first appeared on PharmaShots.
